Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

681 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Thalidomide in the management of multiple myeloma.
Barlogie B, Tricot G, Anaissie E. Barlogie B, et al. Semin Oncol. 2001 Dec;28(6):577-82. doi: 10.1016/s0093-7754(01)90027-2. Semin Oncol. 2001. PMID: 11740812 Review.
Recovery from neutropenia can be predicted by the immature reticulocyte fraction several days before neutrophil recovery in autologous stem cell transplant recipients.
Grazziutti ML, Dong L, Miceli MH, Cottler-Fox M, Krishna SG, Fassas A, van Rhee F, Barlogie BM, Anaissie EJ. Grazziutti ML, et al. Bone Marrow Transplant. 2006 Feb;37(4):403-9. doi: 10.1038/sj.bmt.1705251. Bone Marrow Transplant. 2006. PMID: 16400338
Testing recombinant adeno-associated virus-gene loading of dendritic cells for generating potent cytotoxic T lymphocytes against a prototype self-antigen, multiple myeloma HM1.24.
Chiriva-Internati M, Liu Y, Weidanz JA, Grizzi F, You H, Zhou W, Bumm K, Barlogie B, Mehta JL, Hermonat PL. Chiriva-Internati M, et al. Blood. 2003 Nov 1;102(9):3100-7. doi: 10.1182/blood-2002-11-3580. Epub 2003 Jul 10. Blood. 2003. PMID: 12855576
Gene expression profiling and multiple myeloma.
Shaughnessy J Jr, Zhan F, Barlogie B, Stewart AK. Shaughnessy J Jr, et al. Best Pract Res Clin Haematol. 2005;18(4):537-52. doi: 10.1016/j.beha.2005.02.003. Best Pract Res Clin Haematol. 2005. PMID: 16026736 Review.
Recombinant interferon gamma in hairy cell leukemia, multiple myeloma, and Waldenstrom's macroglobulinemia.
Quesada JR, Alexanian R, Kurzrock R, Barlogie B, Saks S, Gutterman JU. Quesada JR, et al. Am J Hematol. 1988 Sep;29(1):1-4. doi: 10.1002/ajh.2830290102. Am J Hematol. 1988. PMID: 3140655
These results suggest that there is only minimal activity of rIFN-gamma as a single agent in neoplasms of B-cell origin....
These results suggest that there is only minimal activity of rIFN-gamma as a single agent in neoplasms of B-cell origin....
Prognostic factors with high-dose melphalan for refractory multiple myeloma.
Barlogie B, Alexanian R, Smallwood L, Cheson B, Dixon D, Dicke K, Cabanillas F. Barlogie B, et al. Blood. 1988 Dec;72(6):2015-9. Blood. 1988. PMID: 3196876
Therapy of primary resistant and relapsed multiple myeloma.
Barlogie B, Alexanian R. Barlogie B, et al. Onkologie. 1986 Aug;9(4):210-4. doi: 10.1159/000216008. Onkologie. 1986. PMID: 3531948
High dose melphalan for refractory myeloma--the M.D. Anderson experience.
Barlogie B, Dicke KA, Alexanian R. Barlogie B, et al. Hematol Oncol. 1988 Apr-Jun;6(2):167-72. doi: 10.1002/hon.2900060217. Hematol Oncol. 1988. PMID: 3292374 Clinical Trial. No abstract available.
681 results
Jump to page
Feedback